We hypothesized that after reaching the target regions, LHRH-NBs, the contrast agent with extremely high penetration ability, could bind to the LHRH receptor expressed on the surface of the ovarian cancer cells through the LHRH antibody on the surface of the LHRH-NBs, and actively adhere to the tumor cells for a long time and aggregate in the tissue cells. This evidence concerns the gene GNRH1 and ovarian cancer.